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Subsequent studies showed it to be a family of lipoproteins whose wide density range overlaps those of low and high density lipoproteins. Although clinical interest in this particle was limited for many years, it was stimulated again in the late 1970s with the discovery that high concentrations of Lp(a) may be associated with coronary heart disease (CHD). 2 Numerous follow-up studies con®rmed that Lp(a) is an independent risk factor for CHD and that raised values are associated with the severity of CHD 3±5 and with an increased risk of future cardiac events. 6, 7 The relative risk of myocardial infarction has been reported to be 1´75-fold higher when Lp(a) levels are raised above 300 mg/L. 8 Clinical interest in Lp(a) has stimulated the development of commercial methods for its determination. Currently, over 15 methods are available, varying in principle, antibody speci®-city, standardization and method of detection. This personal view considers the impact that different methodological approaches have had on the interpretation of Lp(a) levels in clinical studies and the initiatives now being taken to standardize the measurement of this heterogeneous particle.
STRUCTURE OF Lp(a)
Lp(a) is a complex lipoprotein consisting of a central core of LDL covalently linked by a single disulphide bond to a polypeptide chain of apolipoprotein(a) [apo(a)] (see Fig. 1 ). 9, 10 The structural gene for apo(a) is located on chromosome six, with the gene for plasminogen being nearby. The polypeptide chains of apo(a) and plasminogen contain a number of sequence overlaps. Plasminogen contains a C-terminal serine protease sequence and ®ve distinct domains, termed kringles (K). Apo(a) contains ten sequences that closely resemble plasminogen's K4, a K5-like domain and an equivalent protease sequence domain, albeit with no enzyme activity. Of the ten K4-like domains in apo(a), nine (K4.1 and K4.3±K4.10) are present as one copy, but K4.2 may show a variable number of identical repeats ranging from three to over 40. These variable repeats lead to variation in the molecular weight of Lp(a) from 400 000 to 700 000, and allows the detection of up to 40 distinct isoforms on isoelectric focusing. Following the nomenclature of Utermann, 9 six isoforms were initially identi®ed as B, F, S1, S2, S3 and S4, with B representing small isoforms (up to ten K4.2 repeats) and S4 large isoforms (over 35 K4.2 repeats).
KITS FOR THE MEASUREMENT OF Lp(a)
The size heterogeneity of Lp(a) and the inclusion of LDL and plasminogen-like sequences in its structure have provided major challenges to the design of immunoassays for its measurement. A variety of methodological approaches have been used. Early methods included radial immunodiffusion, 11 radioimmunoassay 12 and electroimmunoassay, 13 but these were superseded by more sensitive, less labour-intensive enzymelinked immunosorbent assays (ELISAs) and immunoradiometric assays (IRMAs). 14, 15 More recently, immunoturbidimetric and nephelometric methods have become more popular due to their rapid throughput, ease of automation and now improved precision. 16, 17 The kits that are available vary in the calibrators they provide and the speci®city of the antibodies they employ. Some examples are provided in Table 1 . The calibrators may be provided lyophilized to be reconstituted in saline or in serum, lyophilized and bound to microtitre plate wells or as liquid stable solutions. There is variation in their composition. Ideally, a calibrator is identical in composition to the analyte being measured. For Lp(a) this is impossible to achieve because of the variety of naturally The speci®city of the antibodies also varies. Plasminogen cross-reactivity is not usually a signi®cant factor at physiological concentrations 18 and LDL cross-reactivity may be minimized by immunoabsorption of the antibody population with LDL or by selection of suitable monoclonal antibodies. However, the kits vary in their recognition of the K4.2 repeat sequence. This may be of signi®cance since antibodies that recognize this sequence may recognize a fractionally greater amount of high molecular weight isoforms compared to small isoforms (see results of kit comparisons, below). Only the manufacturers of the Mercodia RIA kit (Mercodia AB, Uppsala, Sweden) qualify that their antibody does not recognize this epitope. The differing sizes of apo(a) isoforms may be of signi®cance if immunonephelometric and turbidimetric methods are used, since larger isoforms may give larger size immune complexes. 19 This may also be of signi®ance in electroimmunoassay formats since larger isoforms may have different gel migration properties from smaller isoforms. In`sandwich' ELISAs, a popular antibody combination that has been used is a capture apo(a) antibody bound to a solid phase to isolate Lp(a) particles and subsequent detection by (enzyme-linked) anti-LDL or anti-apo B antibody since each Lp(a) particle includes only one such moiety. 20 The Mercodia IRMA (Mercodia AB) method, however, uses two different anti-apo(a) antibodies (the detector antibody is 125 I-linked).
RESULTS OF KIT COMPARISONS
Within-laboratory comparisons of results often report correlationcoef®cients of 0´9 or greater but with varying degrees of bias between methods. Thus, Gaw et al., comparing the Innotest Lp(a)
ELISA (Chromogenix AB, Molndal, Sweden) with a latex-agglutination method, reported excellent agreement, a correlation coef®cient of 0´97 and no systematic bias between the methods. 21 Stroop et al. compared the Macra (Terumo Medical Corp, Elkton MD, USA) and Immubind (American Diagnostics Inc, Greenwich CT, USA) ELISA methods and reported a correlation coef®cient of 0´92. 22 No systematic bias was found between the methods but poor agreement was noted for some samples with no obvious cause. A good correlation of 0´97 was also found between the Biopool AB (Umea, Sweden) and Immuno Ltd (Sevenoaks, UK) ELISAs by Dagen et al., although results of the latter were signi®cantly higher than the former and again there was poor agreement between some samples. 23 Marz et al. reported a 1´5-fold bias between the Immuno ELISA and the Pharmacia IRMA (Uppsala, Sweden) and also noted that the effect of these differences would have been to classify 36 of the 93 patients in their study above the 300 mg/L cut-off value by the Immuno method but only 21 by the Pharmacia method. 24 A cross-kit calibrant comparison concluded that most of the difference was due to the adoption of different calibration protocols.
Baldo-Enzi et al., in a comparison of ®ve commercial methods, also found poor agreement for a considerable number of samples. 25 This study carried out method comparisons by both difference plots and correlation coef®-cients. Reasonable correlation coef®cients were reported (indicating the degree of a relationship between two methods), but difference plots highlighted considerable differences between the methods (ranging from 7300 to +640 mg/L) and the authors concluded that due to a combination of systematic bias and interindividual differences none of the ®ve methods could be considered comparable (see Fig. 2 ).
Between-laboratory comparisons have also indicated both underlying biases and interindividual differences. 26±28 Mackness 26 circulated ®ve specimens in a multi-centre study group using four methods and, amongst the differences that were found, the Pharmacia IRMA method could report a value twice that of the Immuno ELISA method for one specimen, but both methods could report virtually the same result for another specimen. In an international survey, Labeur et al. 27 also found large interlaboratory differences, even within method groups, and concluded that many of the differences were due to the lack of a common calibrant. Poor precision was also noted for some of the methods. The overall number of reports of comparisons between laboratories is, however, small and because these studies have often included only a relatively low number of participants it has been particularly dif®cult to obtain a better estimate of method imprecision. Larger studies are warranted; a between-labora- It has been reported that much of the bias between methods may be overcome when a common calibrant is adopted. 29 Albers and Marcovina, in a comparison of nine commercial kits (six ELISAs and three immunoturbidimetric methods), found that results were broadly comparable when calibrated with a single S2 isoform (containing 21 K4.2 repeats) serum standard. 29 The in¯uence of variation in apo(a) isoform size as a cause of intra-individual differences was subsequently evaluated by Marcovina et al. 30 Three sandwich ELISA systems were employed, each of which used a common apo(a) capture antibody bound to the solid phase of a microtitre plate, but different detection antibodies. The ®rst detection antibody was speci®c for the K4.2 repeat sequence, the second was for K4 type 9 and the third for apo B-100. The three ELISAs were calibrated using a common serum calibrant containing 21 K4 domains whose value was assigned in nmol/L. Lp(a) was measured in serum samples from 723 individuals, each of whom had a single apo(a) isoform in their circulation. Results showed that methods 2 and 3 were closely comparable but results for method 1 (which employed the K4.2-speci®c antibody) were lower when the number of K4 repeats was less than 21 and greater when there were over 21 repeats. 31 These results may be explained by the lower immunoreactivity of low molecular weight isoforms for an antibody that recognizes the K4.2 repeat sequence. The authors also emphasize the importance of assigning calibrant values in terms of molar rather than mass units to account for the variation in molecular weight of individual isoforms.
Although the two effects of differences in calibrants and speci®city of antibodies for the K4.2 repeat sequence probably account for much of the reported differences in results, Albers and Marcovina also provide evidence that variation in the number of K4.2 repeats in¯uences results in methods using anti apo B-100 recognition antibodies. 29 In a comparison of two ELISAs, one of which used an apo(a) detection antibody and the other an apo B-100 detection antibody, they found that samples with smaller apo(a) isoforms gave higher results in the apo B-100 system. The conclusion was that this was due to the greater availability of apo B-100 recognition sites in the smaller molecular weight Lp(a) isoforms.
Despite the dif®culties in measuring Lp(a), a large number of methods remain available. Factors such as variable antibody speci®city and inherent imprecision are of importance in determining method comparability, but the overriding concern for many commentators is the current absence of a common (reference) standard that kit manufacturers can employ to assign values to their own (secondary) materials.
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INTERPRETATION OF Lp(a) IN CLINICAL STUDIES
Factors other than methodological limitations may also be important in the interpretation of Lp(a) results. Population Lp(a) values follow a skewed distribution with median values lower than mean values, thus necessitating use of nonparametric statistics when evaluating data. Racial differences have been reported, with Blacks having a less skewed distribution and higher levels than Whites. 32 Age-related differences are also relevant. Lp(a) has been reported to increase during the early years of life, reaching a plateau in adulthood. 33 Sex-related differences may arise in later years, with women reported to have higher values after the menopause. 34 In non-insulin-dependent diabetes mellitus, Lp(a) has been reported to be increased compared to controls, 35 but this has not been a consistent ®nding. 36 A number of studies have reported that Lp(a) is increased in renal disease 37 and in patients undergoing haemodialysis. 38 There is also some evidence that Lp(a) may show biological variation. When monitored in healthy individuals over a 1-year period Lp(a) showed discernible peaks and troughs by a variety of methods. 39 Lp(a) may also be an acute-phase reactant, with levels increasing after myocardial infarction, 40 stroke 41 and coronary artery bypass graft (CABG). 42 It may also play an important role in in¯ammation and it has been recommended that Lp(a) should not be measured for at least 1 month following an acute clinical event. 43 What evidence there is for an association between Lp(a) and cardiovascular disease has come from large population-based prospective, cross-sectional and case-control studies. The importance of large studies is that they are more likely to overcome the restrictions imposed by physiological factors and the methodological dif®culties of measuring Lp(a). The dif®culties in interpreting Lp(a) levels when smaller numbers of patients are evaluated have recently been highlighted in a number of longitudinal studies. Thus, during growth hormone therapy, initial reports indicated that Lp(a) may show signi®-cant rises, 44±46 but these results were refuted in other studies that could not demonstrate any change. 47, 48 One recent study has also reported a decrease. 49 During pregnancy, depending on the method used, Lp(a) may show either a signi®cant rise or no signi®cant change during the second trimester. 50, 51 During an 18-week walking programme, Kearney et al. reported that Lp(a) showed signi®cant rises when measured by an immunoturbidimetric method but no change with an immunonephelometric method. 52 The reported changes in Lp(a) during CABG are also confounding. Although most reports suggest that Lp(a) rises during such surgery, one recent study reported no change. 53 Fortmann and Marcovina have highlighted the fact that no studies have evaluated the impact of method inaccuracy on the interpretation of clinical data. 54 To date, laboratory-based method evaluations and clinical studies have been carried out largely in isolation from each other. The need to improve current methodology as a prerequisite to allowing a more con®dent interpretation of clinical data has been widely agreed and led the International Federation of Clinical Chemistry to establish a working group during 1996 for the standardization of Lp(a) assays [IFCC WG Lp(a)].
TOWARDS STANDARDIZATION OF Lp(a) ASSAYS
The IFCC WG Lp(a) standardization project has been divided into three phases:
1 Assessment of the analytical performance of existing Lp(a) assays and testing of commercial Lp(a) calibrator materials for commutability. 2 Development of a common calibrator for Lp(a) measurement, including stability monitoring, evaluation of assay performance in optimized assays, and choice of a selected Lp(a) method for value assignment. 3 Testing of a panel of fresh-frozen serum samples for method harmonization and bias estimation after the calibration of test systems with the secondary Lp(a) reference standard.
The ®ndings of phase 1 have recently been reported. 55 Thirty-three laboratories participated in 12 countries, including the six laboratories of the working group and 26 diagnostic companies. The diagnostic companies supplied their Lp(a) calibrators as proposed reference materials (PRMs; eight PRMs were supplied in total), which were circulated among the laboratories and analysed by six different method types (17 immunoturbidimetric, nine ELISA, seven immunonephelometric, two radioimmunoassay, two electroimmunoassay, two dissociationenhanced lanthanide¯uoroimmunoassay (DEL-FIA), one Lp(a)-cholesterol assay; 40 methods in total). Each laboratory was also supplied with two liquid frozen control serum samples and were asked to prepare an in-house serum pool by combining serum samples from two or more normotriglyceridaemic subjects with Lp(a) 5400 mg/L. The following assessments were carried out:
. Comparability of results of the eight PRMs for the different method types. . Between-batch precision by repeat analysis of all the PRMs, frozen control serum samples and the in-house prepared pools. . Linearity by dilution in phosphate-buffered saline of all the PRMs, frozen control serum samples and the in-house prepared pools. . Parallelism by comparison of linearity characteristics of the PRMs, frozen control serum samples and the in-house prepared pools.
Large differences in mean values were found for the different method types for the eight PRMs. In addition it was noted that the withinmethod inter-laboratory coef®cients of variation (CVs) were also high, the lowest being 22% but in one case being as high as 70%. The combination of poor comparability and high withinmethod CVs contributed to the high CVs noted for each PRM when the means for each method were combined. Of interest, however, was that when the data for`poorly performing assays' were removed there was a great improvement in the overall CVs for the remaining assays. Poorly performing assays were de®ned arbitrarily by the working group as those that were non-linear and/or imprecise for the in-house serum pool or which gave an unexpectedly low value for one of the liquid frozen serum pools. Thus, although these results con®rmed the poor betweenmethod comparability found in previous studies, encouragingly they also suggested that thè better performing assays' are capable of achieving close agreement.
Approximately 40% of the methods (both commercial kits and in-house research assays) were unable to produce a linear dose±response curve for a medium to high level serum pool. Further, approximately half of all methods lacked adequate precision characteristics and/ or linearity. The calibrators also showed variable parallelism to the in-house prepared serum pool and one of the liquid frozen control serum samples. Such method de®ciencies were deemed to be the concern of the manufacturer rather than of the working group, and it was commented that the continued availability of the`poorly performing assays' only hampers current efforts to harmonize Lp(a) assays and that they have probably contributed to a greater extent than was previously recognized to the poor comparability between methods.
Separate studies showed that the PRMs varied markedly in their isoform content, that their electrophoretic mobility characteristics sometimes compared poorly to serum samples, that their triglyceride and cholesterol content varied and that they sometimes contained Lp(a) fragments such as free apo(a). It was also noted that most of the commercially available antibodies recognize the K4.2 repeat sequence, highlighted by Marcovina et al. 30 as a cause for methodological discrepancies.
Overall, phase 1 con®rms that a universal standard is needed and that a signi®cant number of the currently available methods should either be optimized or withdrawn. It was thought that one of the currently available commercial standards might be a suitable candidate for a secondary reference material.
CONCLUSION
The differences in results between Lp(a) methods are considerable and these differences may in part be responsible for the confusion that currently exists in interpreting clinical data. Given the heterogeneous nature of the Lp(a) particle, the variety of methods available for its determination, the physiological factors affecting its levels and the absence of recommendations for its measurement, it may not be altogether surpising that so many apparently confounding results are generated. The initiative now being taken by the IFCC WG Lp(a) to produce a reference material is an important ®rst step towards ensuring that results of different methods become more comparable. Results of Lp(a) measurements should be interpreted by non-parametric statistics in studies suf®ciently large to represent adequately the numerous apo(a) isoforms, using methods that assign values in terms of molar rather than mass units and using antibodies whose characteristics in terms of their isoform recognition have been de®ned. With better performing methods may come a better understanding of the role and function of this particle. Figure 1 is reproduced with kind permission of Diasorin Ltd.
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